Get a Brexit deal for the sake of public health, ABPI urges negotiators

The pharmaceutical sector could be one of the worst affected by a no-deal Brexit, with interruptions to medicine imports and supply chain products putting at risk patients’ health in the short-term at least.

Another consideration for the longer term, but also of great importance to public health, is how the issue of regulation of medicines will be resolved, and whether the UK’s involvement in the European Medicines Agency (EMA) will continue, or whether its own Medicines and Healthcare products Regulatory Agency (MHRA) will have to take on all of the agency’s functions.

"The best way to protect patients and public health in the UK and in the European Union is to agree future cooperation between the MHRA and the EMA"